JCRI – ABTS and USMI to Present a Two-year Follow-up of Phase I Clinical Trial Using Cold Atmospheric Plasma for the Treatment of Solid Tumors at Israeli Society of Surgical Oncology
“Phase I Clinical Trial of Canady Helios Cold Atmospheric Plasma (CHCP) Treatment for Patients with Advanced Stage IV Metastatic and Recurrent Solid Tumors: A Novel Potential 4th Treatment Arm for Cancer”
Dr. Canady stated, “Metastatic and recurrent Stage IV solid tumors have a poor overall survival (OS) despite the advancement of surgery, chemotherapy, radiation, and immunotherapy. The CHCP Trial was a Phase I, multiple-center, open labelled, prospective controlled trial which enrolled eligible subjects undergoing surgery and intra-operative CHCP treatment. Between March 2020 to April 2021, twenty (20) patients were recruited from Rush University Medical Center Chicago, Illinois and Sheba Medical Center Tel HaShomer, Israel. Patients received intra-operative CHCP treatment at the operative site after the tumor was removed. The primary end point was safety, and the secondary end point was to demonstrate ablation and slowing down tumor growth in cancer patients without damaging surrounding normal biological tissue.”
Patients from 26 to 85 years of age (mean age 59) were enrolled in the study. Physiological data was recorded throughout surgery (i.e. blood pressure, pulse, body temperature, End Tidal CO2, and oxygen saturation which demonstrated no significant changes (p > 0.05) during the intra-operative CHCP treatment period). There were no adverse events related to CHCP.
Contacts
US Medical Innovations, LLC
Kenniah Chestnut, Esq. VP Corporate Affairs
301-270-0147
KChestnut@usmedinnov.com
www.usmedinnovations.com